Edwards Lifesciences Form 4: Small tax withholding by CVP Daniel Lippis

Rhea-AI Filing Summary

Edwards Lifesciences (EW) – Form 4 insider filing

Corporate Vice President Daniel J. Lippis reported a single transaction dated 07 July 2025. Using transaction code F (shares withheld to cover taxes), 333 shares of common stock were disposed of at an average price of $76.79 per share. Following the tax-related withholding, Lippis’ direct beneficial ownership stands at 26,115.9103 shares.

No derivative securities were reported and no other acquisitions or dispositions were disclosed. The filing notes the routine quarterly purchase activity under the company’s Employee Stock Purchase Plan, but those acquisitions are not itemised in the tables. Given the small size of the tax-related disposition (≈1.3 % of the insider’s holdings) and the absence of open-market sales, the transaction is unlikely to have a material impact on the company’s share supply or insider-ownership sentiment.

Insights

Securities Analyst

TL;DR: Routine tax-withholding of 333 shares; negligible impact on insider ownership or investor sentiment.

The Form 4 shows a code F transaction, indicating shares withheld to satisfy tax obligations from equity compensation. Only 333 shares were surrendered, leaving the executive with more than 26 k shares. No open-market sale occurred, and no derivatives were exercised. The percentage reduction is immaterial and typical for senior management following vesting events. Accordingly, the filing conveys no directional signal about management’s view of Edwards Lifesciences’ valuation and should be regarded as routine administrative activity.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lippis Daniel J.

Role CVP, JAPAC

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	333	$76.79	$26K

Holdings After Transaction: Common Stock — 26,115.91 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2025		F		333	D	$76.79	26,115.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

	Linda J. Park, Attorney-in-Fact	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Edwards Lifesciences (EW) shares did Daniel J. Lippis dispose of?

333 shares were withheld for taxes in the reported transaction.

What was the transaction price listed in the Form 4 for EW?

The shares were valued at $76.79 each for the tax-withholding transaction.

What is Daniel J. Lippis’ remaining direct ownership in EW after the filing?

He now directly owns 26,115.9103 shares.

Was the July 7, 2025 EW insider transaction an open-market sale?

No. Code F indicates shares were withheld to cover taxes, not sold on the open market.

Did the Form 4 report any derivative security activity for EW?

No derivative securities were acquired or disposed of in this filing.